Moderna, Inc.'s hopes of marketing a combination vaccine against influenza and COVID-19 have moved a step further following promising early-stage results that demonstrated it was as effective as standalone jabs for the respective viruses.
Key takeaways
- Moderna hopes mRNA-1083 can win approval in 2025
- A COVID-19/flu vaccine combo could increase compliance and cut healthcare costs
- Analysts seem more interested in whether the US
The US biotech has presented topline interim data from an ongoing Phase I/II trial evaluating mRNA-1083, a combination of Moderna's next-generation COVID-19 vaccine mRNA-1283 and mRNA-1010, its investigational flu vaccine
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?